BOSTON, Massachusetts — August 14, 2025 — Leads & Copy — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) has announced the enrollment and dosing of the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA). The trial is taking place at Brigham and Women’s Hospital in Boston, Massachusetts.
The six-month open-label study (ClinicalTrials.gov Identifier: NCT06868628) will assess foralumab’s potential to reduce neuroinflammation via regulatory T cells through a non-systemic delivery approach. Participants will receive treatment over eight dosing cycles to determine if the approach can slow disease progression and improve quality of life.
Dr. Vikram Khurana, MD, PhD, Tracy T. Batchelor Endowed Chair in Neurology, Division Chief of Movement Disorders and Director of the MSA Center of Excellence at Brigham and Women’s Hospital and Principal Investigator of the MSA trial, said the trial represents an opportunity to explore a treatment aimed directly at the immune processes that may drive the disease. Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, added that dosing the first patient marks an important milestone and that the company is hopeful foralumab’s mechanism can open new doors in treating diseases where inflammation and degeneration are intertwined.
MSA is a rare, rapidly progressive neurodegenerative disorder affecting movement, balance, and autonomic functions. It affects an estimated 15,000–50,000 people in the United States, and there are no FDA-approved treatments that alter its course.
Paul Spencer, Business Development, and Investor Relations, Tiziana Life Sciences Ltd, +44 (0) 207 495 2379, email: info@tizianalifesciences.com
Source: Tiziana Life Sciences
